

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Baricitinib, long COVID and disability, effectiveness of monoclonals and antivirals on subvariants

Peer reviewed journals featured:

- A randomised controlled trial of baricitinib in hospitalised COVID-19 patients [here](#) and associated commentary [here](#)
- A narrative review on COVID-19-associated fungal infections [here](#)
- Observational studies on:
 - Factors associated with cancer treatment delay among US COVID-19 patients [here](#)
 - US adults' beliefs about harassing or threatening public health officials [here](#)
 - Rates and factors associated with documentation of diagnostic codes for long COVID in the US Veterans Affairs health care system [here](#)
 - Association of receiving a fourth dose of Comirnaty (Pfizer) vaccine with SARS-CoV-2 infection in healthcare workers in Israel [here](#)
 - Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy [here](#)
 - Ranking the effectiveness of non-pharmaceutical interventions in UK universities with vaccinated population [here](#)
 - Evaluating the performance of US Centers for Disease Control and Prevention COVID-19 community levels as leading indicators of COVID-19 mortality [here](#)
 - The risk of COVID-19 related deaths for Omicron BA.1 compared with Delta [here](#) and associated commentary [here](#)
- Modelling studies on:
 - Prediction of hospital-onset COVID-19 infections using patient-contact networks [here](#)
 - Remote COVID-19 assessment in primary care (RECAP) risk prediction tool [here](#) and associated commentary [here](#)
- Commentary on:
 - Long COVID and disability [here](#)
 - Affordable SARS-CoV-2 protein vaccines for the pandemic endgame [here](#)
 - Masks as a condition of entry in UK healthcare settings [here](#)

Letters and correspondence discussed:

- Efficacy of monoclonals and antiviral drugs against Omicron BA.2.12.1, BA.4, BA.5 subvariants [here](#)
- Development of resistance-associated mutations after sotrovimab administration in high-risk people infected with Omicron [here](#)
- Chronic glucocorticoid maintenance treatment associated with SARS-CoV-2 infection risk in patients with systemic lupus erythematosus who received vaccination [here](#)

Pre-peer review articles featured:

- The health impact of long COVID during the 2021-2022 Omicron wave in Australia [here](#)
- Coenzyme Q10 as treatment of post COVID-19 condition [here](#)
- Omicron BA.2 breakthrough infection enhances cross-neutralisation of BA.2.12.1 & BA.4/BA.5 [here](#)
- Association of BA.4/BA.5 Omicron lineages with immune escape and clinical outcome [here](#)
- Risk of Omicron BA.5 infection in individuals exposed to prior SARS-CoV-2 variants [here](#)
- Profiling long COVID across different SARS-CoV-2 variants [here](#)
- Dysnatraemia during hospitalisation and post COVID-19 mental fatigue [here](#)
- Comirnaty (Pfizer) vaccine effectiveness against Omicron in children aged 5-11 years [here](#)

Guidance and reports

- The World Health Organization published its weekly epidemiological report on COVID-19 [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) published recommendations on COVID-19 vaccine use in children aged 6 months to 5 years [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- TGA advice on the use of nirmatrelvir + ritonavir (PAXLOVID) post labelled expiry date [here](#)

News and blogs

- Heart disease after COVID-19 [here](#)
- Ontario hospitals close wards as nursing shortage bites [here](#)
- NHS staff absences in July surged amid ongoing pressure on hospitals [here](#)

[Click here](#) to subscribe to, and unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).